AR-15512 achieved statistical significance for multiple sign and symptom endpoints in patients with dry eye disease, according to a press release from Aerie Pharmaceuticals.
AR-15512, a TRPM8 agonist, demonstrated positive topline results in COMET-1, a phase 2b clinical study investigating the ophthalmic solution to treat dry eye disease.
COMET-1 is a randomized, double-masked, vehicle-controlled study that enrolled 369 patients across three arms. Patients were randomly assigned to receive AR-15512 (0.0014%), AR-15512 (0.003%) or vehicle and were dosed twice a day over 84 days.
The study showed